There are currently 1995 clinical trials in Chicago, Illinois looking for participants to engage in research studies. Trials are conducted at various facilities, including Northwestern University, Rush University Medical Center, University of Chicago and University of Chicago Comprehensive Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL
NCT06468202
Recruiting
The overall goal of this large, pragmatic, comparative effectiveness trial is to test the hypothesis that among at-risk individuals, 162 mg/day aspirin is superior to 81 mg/day in preventing Hypertensive disorders of pregnancy (HDP), and that there are multiple factors associated with adherence with aspirin therapy that will be important to identify to enable optimal implementation of study findings and population-level benefits.
Gender:
FEMALE
Ages:
Between 14 years and 35 years
Trial Updated:
04/30/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Hypertensive Disorders of Pregnancy, Preeclampsia, Gestational Hypertension
Register for Updates
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
NCT05985161
Recruiting
The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, or another solid tumor that makes a higher than normal amount of XPO1 or has genetic changes that increase the activity of XP01.
Gender:
ALL
Ages:
12 months and above
Trial Updated:
04/29/2025
Locations: Ann & Robert H. Lurie Children'S Hospital of Chicag, Chicago, Illinois
Conditions: Wilms Tumor, Rhabdoid Tumor, Malignant Peripheral Nerve Sheath Tumors, MPNST, Nephroblastoma, XPO1 Gene Mutation, Solid Tumor
Register for Updates
Understanding and Addressing Disparities in Cancer Therapy Induced Inflammation and Associated Endothelial Dysfunction
NCT05223322
Recruiting
Very little is understood about the off-target vascular mechanisms of anti-cancer drug toxicity and the impact of exercise on these changes. Much of what has been learned about molecular pathways regulating vascular endothelial function has been established by logical expansion of knowledge obtained through experimental studies (e.g., discovery of endothelium-derived relaxing factor/nitric oxide). Within the last 10 years technological advancements of -omics approaches, such as RNA-sequencing an... Read More
Gender:
FEMALE
Ages:
Between 18 years and 100 years
Trial Updated:
04/29/2025
Locations: University of Illinois Chicago, Chicago, Illinois
Conditions: Breast Cancer
Register for Updates
A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Thalamotomy for the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease
NCT04991831
Recruiting
The objectives of this study are to collect the long-term safety and effectiveness data of performing thalamotomy for tremor dominant Parkinson's Disease (TDPD) using the Exablate Neuro system.
Gender:
ALL
Ages:
Between 30 years and 99 years
Trial Updated:
04/29/2025
Locations: Rush University, Chicago, Illinois
Conditions: Tremor Associated With Tremor Dominant Parkinson's Disease
Register for Updates
Duloxetine RCT on Postop TKA Outcomes
NCT05086393
Recruiting
The aim of this study is to determine if duloxetine is associated with differences in post-operative pain, patient-reported outcome measures, and opioid consumption in patients undergoing primary total knee arthroplasty compared to patients who do not receive the medication. If so, duloxetine has the potential to become widely incorporated into the multi-modal analgesic regimen given to patients following knee replacements.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/29/2025
Locations: Rush University medical Center, Chicago, Illinois
Conditions: Pain, Postoperative, Total Knee Arthroplasty
Register for Updates
An Intervention to Reduce Sedentary Behavior for Black Adults With Chronic Kidney Disease
NCT06754280
Recruiting
RESET-CKD is evaluating an intervention to support Black adults with chronic kidney disease (CKD) to reduce their sedentary (e.g., sitting) time. Half of the participants will be randomized to the intervention, where the goal is to support individuals to reduce their sitting time, and the other half will be randomized to an attention control condition that provides CKD-related education not related to sedentary behavior. All participants will be followed for 12 weeks.
Gender:
ALL
Ages:
Between 35 years and 80 years
Trial Updated:
04/29/2025
Locations: UI Health/University of Illinois Chicago, Chicago, Illinois
Conditions: Chronic Kidney Disease(CKD)
Register for Updates
Proteogenomic Monitoring and Assessment of Liver Transplant Recipients
NCT01644903
Recruiting
This study is being done to test blood, urine and tissue samples to see if this can help decide if CKD (Chronic Kidney Disease), AR (Acute Rejection) and HCV (Hepatitis C Virus) can be identified in its early stages. CKD damage to the kidneys, AR and HCV all lower the body's ability to function properly. Early detection of these conditions could assist with successful treatment and possibly lead to less repeat organ transplants.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: Northwestern Memorial Hospital, Chicago, Illinois
Conditions: Liver Transplant, Hepatitis C, Chronic Kidney Disease, Acute Rejection
Register for Updates
MitraClip REPAIR MR Study
NCT04198870
Recruiting
The objective of this randomized controlled trial (RCT) is to compare the clinical outcome of MitraClip™ device versus surgical repair in patients with severe primary MR who are at moderate surgical risk and whose mitral valve has been determined to be suitable for correction by MV repair surgery by the cardiac surgeon on the local site heart team.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: Northwestern Memorial Hospital, Chicago, Illinois
Conditions: Mitral Valve Regurgitation
Register for Updates
A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression
NCT06285916
Recruiting
The purpose of this research study is to test the study drug, NORA520, as a possible treatment for severe postpartum depression (PPD). The trial aims to determine: * How well NORA520 is tolerated and what side effects it may cause * If NORA520 reduces depressive symptoms in subjects with severe PPD * The amount of NORA520 in the blood at various times after taking the study drug; this provides information that helps determine how often NORA520 should be taken * In a subset of subjects, the amou... Read More
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
04/28/2025
Locations: Insight Hospital and Medical Center Chicago, Chicago, Illinois
Conditions: Depression, Postpartum, Postpartum Depression, Post-partum Depression, Postnatal Depression, Post-Natal Depression
Register for Updates
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
NCT04262466
Recruiting
Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of brenetafusp in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: The University of Chicago Medical Center, Chicago, Illinois
Conditions: Select Advanced Solid Tumors
Register for Updates
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
NCT04372615
Recruiting
Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and either inebilizumab (investigational agent) or placebo.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/28/2025
Locations: Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois +1 locations
Conditions: Autoimmune Encephalitis, Encephalitis
Register for Updates
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
NCT06103864
Recruiting
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Research Site, Chicago, Illinois
Conditions: Breast Cancer
Register for Updates